Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV

Koen K.A. Van Rompay, Kristina Abel, Patricia Earl, Pamela A. Kozlowski, Juliet Easlick, Joseph Moore, Linda Buonocore-Buzzelli, Kimberli A. Schmidt, Robert L. Wilson, Ian Simon, Bernard Moss, Nina Rose, John Rose, Marta Marthas

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In a previously developed infant macaque model mimicking HIV infection by breast-feeding, we demonstrated that intramuscular immunization with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins provided partial protection against infection following oral inoculation with virulent SIV. In an attempt to further increase systemic but also local antiviral immune responses at the site of viral entry, we tested the immunogenicity of different orally administered, replicating vaccines. One group of newborn macaques received an oral prime immunization with a recombinant vesicular stomatitis virus expressing SIVmac239 gag, pol and env (VSV-SIVgpe), followed 2 weeks later by an intramuscular boost immunization with MVA-SIV. Another group received two immunizations with live-attenuated SIVmac1A11, administered each time both orally and intravenously. Control animals received mock immunizations or non-SIV VSV and MVA control vectors. Analysis of SIV-specific immune responses in blood and lymphoid tissues at 4 weeks of age demonstrated that both vaccine regimens induced systemic antibody responses and both systemic and local cell-mediated immune responses. The safety and immunogenicity of the VSV-SIVgpe + MVA-SIV immunization regimen described in this report provide the scientific incentive to explore the efficacy of this vaccine regimen against virulent SIV exposure in the infant macaque model.

Original languageEnglish (US)
Pages (from-to)1481-1492
Number of pages12
JournalVaccine
Volume28
Issue number6
DOIs
StatePublished - Feb 10 2010

Fingerprint

Vesiculovirus
Simian immunodeficiency virus
Simian Immunodeficiency Virus
Vesicular Stomatitis
Vaccinium
Vaccinia virus
Macaca mulatta
Immunization
Vaccines
immune response
vaccines
immunization
Macaca
Vaccinia
Viruses
Poxviridae
Viral Structural Proteins
oral vaccination
Synthetic Vaccines
vector control

Keywords

  • HIV
  • Oral
  • Pediatric
  • SIV
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques : Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. / Van Rompay, Koen K.A.; Abel, Kristina; Earl, Patricia; Kozlowski, Pamela A.; Easlick, Juliet; Moore, Joseph; Buonocore-Buzzelli, Linda; Schmidt, Kimberli A.; Wilson, Robert L.; Simon, Ian; Moss, Bernard; Rose, Nina; Rose, John; Marthas, Marta.

In: Vaccine, Vol. 28, No. 6, 10.02.2010, p. 1481-1492.

Research output: Contribution to journalArticle

Van Rompay, KKA, Abel, K, Earl, P, Kozlowski, PA, Easlick, J, Moore, J, Buonocore-Buzzelli, L, Schmidt, KA, Wilson, RL, Simon, I, Moss, B, Rose, N, Rose, J & Marthas, M 2010, 'Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV', Vaccine, vol. 28, no. 6, pp. 1481-1492. https://doi.org/10.1016/j.vaccine.2009.11.061
Van Rompay, Koen K.A. ; Abel, Kristina ; Earl, Patricia ; Kozlowski, Pamela A. ; Easlick, Juliet ; Moore, Joseph ; Buonocore-Buzzelli, Linda ; Schmidt, Kimberli A. ; Wilson, Robert L. ; Simon, Ian ; Moss, Bernard ; Rose, Nina ; Rose, John ; Marthas, Marta. / Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques : Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. In: Vaccine. 2010 ; Vol. 28, No. 6. pp. 1481-1492.
@article{6857488e3f114ff086ec21e32ae9035d,
title = "Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV",
abstract = "In a previously developed infant macaque model mimicking HIV infection by breast-feeding, we demonstrated that intramuscular immunization with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins provided partial protection against infection following oral inoculation with virulent SIV. In an attempt to further increase systemic but also local antiviral immune responses at the site of viral entry, we tested the immunogenicity of different orally administered, replicating vaccines. One group of newborn macaques received an oral prime immunization with a recombinant vesicular stomatitis virus expressing SIVmac239 gag, pol and env (VSV-SIVgpe), followed 2 weeks later by an intramuscular boost immunization with MVA-SIV. Another group received two immunizations with live-attenuated SIVmac1A11, administered each time both orally and intravenously. Control animals received mock immunizations or non-SIV VSV and MVA control vectors. Analysis of SIV-specific immune responses in blood and lymphoid tissues at 4 weeks of age demonstrated that both vaccine regimens induced systemic antibody responses and both systemic and local cell-mediated immune responses. The safety and immunogenicity of the VSV-SIVgpe + MVA-SIV immunization regimen described in this report provide the scientific incentive to explore the efficacy of this vaccine regimen against virulent SIV exposure in the infant macaque model.",
keywords = "HIV, Oral, Pediatric, SIV, Vaccine",
author = "{Van Rompay}, {Koen K.A.} and Kristina Abel and Patricia Earl and Kozlowski, {Pamela A.} and Juliet Easlick and Joseph Moore and Linda Buonocore-Buzzelli and Schmidt, {Kimberli A.} and Wilson, {Robert L.} and Ian Simon and Bernard Moss and Nina Rose and John Rose and Marta Marthas",
year = "2010",
month = "2",
day = "10",
doi = "10.1016/j.vaccine.2009.11.061",
language = "English (US)",
volume = "28",
pages = "1481--1492",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques

T2 - Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV

AU - Van Rompay, Koen K.A.

AU - Abel, Kristina

AU - Earl, Patricia

AU - Kozlowski, Pamela A.

AU - Easlick, Juliet

AU - Moore, Joseph

AU - Buonocore-Buzzelli, Linda

AU - Schmidt, Kimberli A.

AU - Wilson, Robert L.

AU - Simon, Ian

AU - Moss, Bernard

AU - Rose, Nina

AU - Rose, John

AU - Marthas, Marta

PY - 2010/2/10

Y1 - 2010/2/10

N2 - In a previously developed infant macaque model mimicking HIV infection by breast-feeding, we demonstrated that intramuscular immunization with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins provided partial protection against infection following oral inoculation with virulent SIV. In an attempt to further increase systemic but also local antiviral immune responses at the site of viral entry, we tested the immunogenicity of different orally administered, replicating vaccines. One group of newborn macaques received an oral prime immunization with a recombinant vesicular stomatitis virus expressing SIVmac239 gag, pol and env (VSV-SIVgpe), followed 2 weeks later by an intramuscular boost immunization with MVA-SIV. Another group received two immunizations with live-attenuated SIVmac1A11, administered each time both orally and intravenously. Control animals received mock immunizations or non-SIV VSV and MVA control vectors. Analysis of SIV-specific immune responses in blood and lymphoid tissues at 4 weeks of age demonstrated that both vaccine regimens induced systemic antibody responses and both systemic and local cell-mediated immune responses. The safety and immunogenicity of the VSV-SIVgpe + MVA-SIV immunization regimen described in this report provide the scientific incentive to explore the efficacy of this vaccine regimen against virulent SIV exposure in the infant macaque model.

AB - In a previously developed infant macaque model mimicking HIV infection by breast-feeding, we demonstrated that intramuscular immunization with recombinant poxvirus vaccines expressing simian immunodeficiency virus (SIV) structural proteins provided partial protection against infection following oral inoculation with virulent SIV. In an attempt to further increase systemic but also local antiviral immune responses at the site of viral entry, we tested the immunogenicity of different orally administered, replicating vaccines. One group of newborn macaques received an oral prime immunization with a recombinant vesicular stomatitis virus expressing SIVmac239 gag, pol and env (VSV-SIVgpe), followed 2 weeks later by an intramuscular boost immunization with MVA-SIV. Another group received two immunizations with live-attenuated SIVmac1A11, administered each time both orally and intravenously. Control animals received mock immunizations or non-SIV VSV and MVA control vectors. Analysis of SIV-specific immune responses in blood and lymphoid tissues at 4 weeks of age demonstrated that both vaccine regimens induced systemic antibody responses and both systemic and local cell-mediated immune responses. The safety and immunogenicity of the VSV-SIVgpe + MVA-SIV immunization regimen described in this report provide the scientific incentive to explore the efficacy of this vaccine regimen against virulent SIV exposure in the infant macaque model.

KW - HIV

KW - Oral

KW - Pediatric

KW - SIV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=75249102897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75249102897&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.11.061

DO - 10.1016/j.vaccine.2009.11.061

M3 - Article

C2 - 19995539

AN - SCOPUS:75249102897

VL - 28

SP - 1481

EP - 1492

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -